George D Demetri

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. doi request reprint Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy
    George D Demetri
    Ludwig Center, Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Clin Oncol 31:2485-92. 2013
  2. pmc Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
    George D Demetri
    Ludwig Center at Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Lancet 381:295-302. 2013
  3. pmc Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure
    George D Demetri
    Center for Sarcoma and Bone Oncology, Ludwig Center at Dana Farber Harvard Cancer Center, Dana Farber Cancer Institute, 450 Brookline Ave, Dana 1212, Boston, MA 02215, USA
    Clin Cancer Res 18:3170-9. 2012
  4. doi request reprint First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study
    George D Demetri
    Harvard Cancer Center, Boston, MA, USA
    Eur J Cancer 48:547-63. 2012
  5. ncbi request reprint Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development
    George D Demetri
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, 44 Binney Street Southwest, Boston, MA 02115, USA
    Hematol Oncol Clin North Am 16:1115-24. 2002
  6. pmc A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors
    George D Demetri
    Ludwig Center at Dana Farber Harvard Cancer Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 15:5910-6. 2009
  7. doi request reprint Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors
    George D Demetri
    Ludwig Center, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 15:6232-40. 2009
  8. pmc Structural reengineering of imatinib to decrease cardiac risk in cancer therapy
    George D Demetri
    Ludwig Center for Cancer Research, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Clin Invest 117:3650-3. 2007
  9. doi request reprint Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors
    George D Demetri
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Semin Oncol 38:S10-9. 2011
  10. doi request reprint Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas
    Sant P Chawla
    International Institute of Clinical Studies, Sarcoma Oncology Center, Santa Monica, CA, USA
    J Clin Oncol 30:78-84. 2012

Detail Information

Publications110 found, 100 shown here

  1. doi request reprint Results of an international randomized phase III trial of the mammalian target of rapamycin inhibitor ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit from prior chemotherapy
    George D Demetri
    Ludwig Center, Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Clin Oncol 31:2485-92. 2013
    ..This large randomized placebo-controlled phase III trial evaluated the mTOR inhibitor ridaforolimus to assess maintenance of disease control in advanced sarcomas...
  2. pmc Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
    George D Demetri
    Ludwig Center at Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA
    Lancet 381:295-302. 2013
    ..We aimed to assess efficacy and safety of regorafenib in patients with metastatic or unresectable GIST progressing after failure of at least imatinib and sunitinib...
  3. pmc Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure
    George D Demetri
    Center for Sarcoma and Bone Oncology, Ludwig Center at Dana Farber Harvard Cancer Center, Dana Farber Cancer Institute, 450 Brookline Ave, Dana 1212, Boston, MA 02215, USA
    Clin Cancer Res 18:3170-9. 2012
    ....
  4. doi request reprint First-line treatment of metastatic or locally advanced unresectable soft tissue sarcomas with conatumumab in combination with doxorubicin or doxorubicin alone: a phase I/II open-label and double-blind study
    George D Demetri
    Harvard Cancer Center, Boston, MA, USA
    Eur J Cancer 48:547-63. 2012
    ..This study evaluated the safety and efficacy of doxorubicin ± conatumumab as first-line systemic therapy for metastatic or locally advanced/unresectable soft-tissue sarcoma...
  5. ncbi request reprint Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development
    George D Demetri
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, 44 Binney Street Southwest, Boston, MA 02115, USA
    Hematol Oncol Clin North Am 16:1115-24. 2002
    ..Integration of signal transduction inhibitors into the armamentarium of cancer therapeutics will undoubtedly continue based on this important paradigm of GIST...
  6. pmc A phase I study of single-agent nilotinib or in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors
    George D Demetri
    Ludwig Center at Dana Farber Harvard Cancer Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 15:5910-6. 2009
    ..To study the safety, tolerability, and pharmacokinetics of the selective tyrosine kinase inhibitor nilotinib as a single agent or in combination with imatinib in patients with advanced imatinib-resistant gastrointestinal stromal tumors...
  7. doi request reprint Phase I dose-escalation and pharmacokinetic study of dasatinib in patients with advanced solid tumors
    George D Demetri
    Ludwig Center, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 15:6232-40. 2009
    ..To determine the maximum tolerated dose, dose-limiting toxicity (DLT), and recommended phase II dose of dasatinib in metastatic solid tumors refractory to standard therapies or for which no effective standard therapy exists...
  8. pmc Structural reengineering of imatinib to decrease cardiac risk in cancer therapy
    George D Demetri
    Ludwig Center for Cancer Research, Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    J Clin Invest 117:3650-3. 2007
    ..The study shows that structural reengineering of a kinase-inhibitory drug to improve tolerability while preserving efficacy is feasible...
  9. doi request reprint Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors
    George D Demetri
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    Semin Oncol 38:S10-9. 2011
    ..In addition, the ability of some TKIs to inhibit alternative targets with potency similar to or greater than their intended primary target (pleiotropic effects) is also discussed...
  10. doi request reprint Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas
    Sant P Chawla
    International Institute of Clinical Studies, Sarcoma Oncology Center, Santa Monica, CA, USA
    J Clin Oncol 30:78-84. 2012
    ..This multicenter, open-label, single-arm, phase II trial was conducted to assess the antitumor activity of ridaforolimus in patients with distinct subtypes of advanced sarcomas...
  11. ncbi request reprint Identification and treatment of chemoresistant inoperable or metastatic GIST: experience with the selective tyrosine kinase inhibitor imatinib mesylate (STI571)
    George D Demetri
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Eur J Cancer 38:S52-9. 2002
    ..This work provides proof of concept to the hypothesis that selective inhibition of aberrant signal transduction can provide important anticancer activity, if the proper signaling pathways are identified and blocked...
  12. pmc Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure
    George D Demetri
    Center for Sarcoma and Bone Oncology, Ludwig Center at Dana Farber Harvard Cancer Center, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Clin Cancer Res 15:5902-9. 2009
    ....
  13. ncbi request reprint ET-743: the US experience in sarcomas of soft tissues
    George D Demetri
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, USA
    Anticancer Drugs 13:S7-9. 2002
    ..There were no treatment-associated deaths. In conclusion, ET-743 is an active chemotherapeutic agent that can induce objective responses and clinical benefit in a subset of patients with metastatic or advanced soft-tissue sarcoma...
  14. ncbi request reprint Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy
    George D Demetri
    Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Clin Breast Cancer 3:45-51. 2002
    ..3 times weekly). Epoetin alfa is, therefore, effective and safe in the management of anemia in patients with breast cancer treated with chemotherapy...
  15. doi request reprint Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules
    George D Demetri
    Center for Sarcoma and Bone Oncology and Ludwig Center of Dana Farber Harvard Cancer Center, Dana Farber Cancer Institute, D1212 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 27:4188-96. 2009
    ....
  16. ncbi request reprint Targeted approaches for the treatment of thrombocytopenia
    G D Demetri
    Dana Farber Cancer Institute, Boston, Massachusetts 02115 6084, USA
    Oncologist 6:15-23. 2001
    ..As a potent stimulator of platelet production, rHuTPO has the potential to reduce the need for platelet transfusions and their attendant complications...
  17. ncbi request reprint Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy
    R Garcia-Carbonero
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, Harvard Medical School, Shields Warren Bldg, Room G530, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 22:1480-90. 2004
    ....
  18. ncbi request reprint Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
    George D Demetri
    Ludwig Center at Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Lancet 368:1329-38. 2006
    ....
  19. ncbi request reprint Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors
    George D Demetri
    Ludwig Center, Dana Farber Harvard Cancer Center, Dana Farber Cancer Institute, D1212, 44 Binney St, Boston MA 02115, USA
    J Clin Oncol 27:3141-7. 2009
    ..Patients with IM C(min) below 1,100 ng/mL showed a shorter TTP and lower rate of clinical benefit (OOBR). Further studies are justified to test whether monitoring IM plasma levels might optimize clinical outcomes for patients with GIST...
  20. pmc Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GI stromal tumor: the ACOSOG Z9001 trial
    Christopher L Corless
    Christopher L Corless, Violetta Kolesnikova, Charles D Blanke, Michael C Heinrich, Oregon Health and Science University, Portland, OR Karla V Ballman, Mayo Clinic, Rochester, MN Cristina R Antonescu and Ronald P DeMatteo, Memorial Sloan Kettering Cancer Center Robert G Maki, Mt Sinai School of Medicine, New York, NY Peter W T Pisters and Shreyaskumar Patel, University of Texas MD Anderson Cancer Center, Houston, TX Martin E Blackstein, Mount Sinai Hospital, Toronto, Ontario, Canada George D Demetri, Dana Farber Cancer Institute, Boston, MA Margaret von Mehren, Fox Chase Cancer Institute, Philadelphia, PA Martin D McCarter, University of Colorado School of Medicine, Aurora, CO and Kouros Owzar, Duke University School of Medicine, Durham, NC
    J Clin Oncol 32:1563-70. 2014
    ..We sought to determine the pathologic and molecular factors associated with patient outcome...
  21. doi request reprint Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib
    Katherine A Janeway
    Pediatric Oncology, Dana Farber Cancer Institute and Department of Medicine, Children s Hospital Boston, Boston, Massachusetts 02115, USA
    Pediatr Blood Cancer 52:767-71. 2009
    ..Sunitinib prolongs survival in adult patients with imatinib-resistant gastrointestinal stromal tumor (GIST). We report the experience with sunitinib in pediatric patients with advanced GIST following failure of imatinib...
  22. pmc Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial
    Suzanne George
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute D1212, 450 Brookline Ave, Boston, MA, USA
    J Clin Oncol 30:2401-7. 2012
    ....
  23. ncbi request reprint Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors
    Jayesh Desai
    Dana Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 13:5398-405. 2007
    ..The objective of this study was to correlate molecular and radiologic patterns of imitinib-refractory disease with existing conventional criteria for disease progression...
  24. ncbi request reprint Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors
    Chandrajit P Raut
    Department of Surgery, Brigham and Women s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 24:2325-31. 2006
    ..To assess the role of surgery in multimodality management of GISTs, we studied postoperative outcomes in patients treated with targeted kinase inhibitors for advanced GIST...
  25. ncbi request reprint NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors
    George D Demetri
    Ludwig Center at Dana Farber Harvard Cancer Center, USA
    J Natl Compr Canc Netw 8:S1-41; quiz S42-4. 2010
    ..The task force met for the first time in October 2003 and again in December 2006 and October 2009. This supplement describes the recent developments in the field of GIST as discussed at the October 2009 meeting...
  26. ncbi request reprint Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib
    Atul B Shinagare
    Department of Imaging, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, United States Department of Radiology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02215, United States Ludwig Center and Department of Medical Oncology, Dana Farber Cancer Institute, 450 Brookline Ave, Boston, MA 02215, United States Electronic address
    Eur J Cancer 50:981-6. 2014
    ..To compare performance of various tumour response criteria (TRCs) in assessment of regorafenib activity in patients with advanced gastrointestinal stromal tumour (GIST) with prior failure of imatinib and sunitinib...
  27. doi request reprint Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate
    Chandrajit P Raut
    Department of Surgery, Brigham and Women s Hospital, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA
    Ann Surg Oncol 17:407-15. 2010
    ..Impact of surgery in IM-resistant patients on second-line sunitinib (SU) is unknown...
  28. pmc Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas
    Suzanne George
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, 44 Binney St, D1210, Boston, MA 02115, USA
    J Clin Oncol 27:3154-60. 2009
    ....
  29. ncbi request reprint Phase 2 trial of aromatase inhibition with letrozole in patients with uterine leiomyosarcomas expressing estrogen and/or progesterone receptors
    Suzanne George
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
    Cancer 120:738-43. 2014
    ..A significant percentage of cases of ULMS express estrogen and/or progesterone receptors (ER and/or PR). To the authors' knowledge, the role of estrogen suppression in disease management is not known...
  30. ncbi request reprint Imatinib targeting of KIT-mutant oncoprotein in melanoma
    Xiaofeng Jiang
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    Clin Cancer Res 14:7726-32. 2008
    ..Biological effects of KIT inhibition in these melanomas remain poorly understood. We sought to investigate further the effects of imatinib in these melanoma subsets...
  31. ncbi request reprint Selective kinase inhibition with daily imatinib intensifies toxicity of chemotherapy in patients with solid tumours
    Suzanne George
    Dana Farber Cancer Institute, Massachusetts General Hospital, Ludwig Center for Cancer Research at Dana Farber Harvard, Harvard Medical School, Boston, MA, USA
    Eur J Cancer 42:864-70. 2006
    ..It remains unclear whether addition of growth factors might improve tolerability for imatininb in combination with cytotoxic chemotherapy...
  32. ncbi request reprint Protein Kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs)
    Anette Duensing
    Department of Pathology, Brigham and Women s Hospital, 75 Francis Street, Boston, MA 02115, USA
    Cancer Res 64:5127-31. 2004
    ..PKCtheta is strongly activated in most GISTs and hence may serve, along with KIT/PDGFRA, as a novel therapeutic target...
  33. ncbi request reprint Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas
    John V Heymach
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Clin Cancer Res 10:5732-40. 2004
    ..This Phase II study was conducted to investigate the safety and efficacy of SU5416 for patients with soft tissue sarcomas...
  34. doi request reprint Imaging features of bone metastases in patients with gastrointestinal stromal tumors
    Anupma Jati
    Department of Radiology, Harvard Medical School, Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Diagn Interv Radiol 18:391-6. 2012
    ..To determine the prevalence and imaging features of bone metastases in patients with gastrointestinal stromal tumors (GISTs)...
  35. doi request reprint Multimodality treatment of mesenteric desmoid tumours
    Monica M Bertagnolli
    Department of Surgery, Brigham and Women s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Eur J Cancer 44:2404-10. 2008
    ..When desmoids arise in the intestinal mesentery, surgical resection is seldom possible without life-altering loss of intestinal function...
  36. ncbi request reprint Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 32-2004. A 68-year-old man with a large retroperitoneal mass
    George D Demetri
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, Boston, USA
    N Engl J Med 351:1779-87. 2004
  37. ncbi request reprint A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors
    David P Ryan
    Division of Hematology Oncology, Massachusetts General Hospital, Harvard Medical School, 100 Blossom Street, Boston, MA 02114, USA
    Oncologist 7:531-8. 2002
    ..To assess the efficacy, tolerability, and pharmacokinetics of ecteinascidin 743 (ET-743) in patients with advanced gastrointestinal stromal tumors (GISTs)...
  38. ncbi request reprint Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors
    Samuel Singer
    Department of Pathology and Surgery, Brigham and Women s Hospital, Boston, MA, USA
    J Clin Oncol 20:3898-905. 2002
    ..The aim of this study was to evaluate the prognostic relevance for KIT mutations in a series of GISTs in which the mutations were evaluated intensively by genomic and cDNA sequencing...
  39. ncbi request reprint Gemcitabine and vinorelbine combination chemotherapy for patients with advanced soft tissue sarcomas: results of a phase II trial
    Palma Dileo
    Department of Medical Oncology, Center for Sarcoma and Bone Oncology and Ludwig Center for Cancer Research, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer 109:1863-9. 2007
    ..This study evaluated the efficacy and tolerability of gemcitabine plus vinorelbine in advanced soft-tissue sarcoma...
  40. ncbi request reprint Leiomyosarcoma of the inferior vena cava: survival after aggressive management
    Hiromichi Ito
    Department of Surgery, Brigham and Women s Hospital, Dana Farber Cancer Institute, and Harvard Medical School, Boston, MA, USA
    Ann Surg Oncol 14:3534-41. 2007
    ..Leiomyosarcoma (LMS) of the inferior vena cava (IVC) is exceedingly rare. The role of adjuvant therapy remains undefined. This study evaluated outcomes after aggressive management...
  41. doi request reprint Predictive value of FIGO and AJCC staging systems in patients with uterine leiomyosarcoma
    Chandrajit P Raut
    Department of Surgery, Brigham and Women s Hospital, Dana Farber Cancer Institute, Harvard Medical School, 75 Francis Street, Boston, MA 02115, United States
    Eur J Cancer 45:2818-24. 2009
    ..Neither has been validated in ULMS. We critically evaluated both systems to determine if either identified patient groups with distinct outcomes...
  42. ncbi request reprint Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
    George D Demetri
    Dana Farber Cancer Institute and Harvard Cancer Center, Boston, MA 02115, USA
    N Engl J Med 347:472-80. 2002
    ..Imatinib mesylate, a selective tyrosine kinase inhibitor, has been shown in preclinical models and preliminary clinical studies to have activity against such tumors...
  43. ncbi request reprint A phase I study of the HSP90 inhibitor retaspimycin hydrochloride (IPI-504) in patients with gastrointestinal stromal tumors or soft-tissue sarcomas
    Andrew J Wagner
    Authors Affiliations Dana Farber Cancer Institute and Harvard Medical School Ludwig Center at Dana Farber Harvard Cancer Center, Boston, Massachusetts University of Michigan, Ann Arbor, Michigan UCLA Division of Hematology Oncology, Santa Monica, California Pinnacle Oncology, Scottsdale, Arizona and Infinity Pharmaceuticals, Inc, Cambridge, Massachusetts
    Clin Cancer Res 19:6020-9. 2013
    ....
  44. doi request reprint Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors
    Andrew J Wagner
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 28:835-40. 2010
    ..The clinical activity of sirolimus in PEComa additionally strengthens the pathobiologic similarities linking PEComas to other neoplasms related to the tuberous sclerosis complex...
  45. ncbi request reprint Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors
    Jayesh Desai
    Brigham and Women s Hospital, Dana Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts 02115, USA
    Ann Intern Med 145:660-4. 2006
    ..Because the ret proto-oncogene is also inhibited by this agent, clinical evaluation of thyroid function was performed...
  46. doi request reprint Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors
    Richard Quek
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Clin Cancer Res 17:871-9. 2011
    ..Pharmacokinetics and preliminary antitumor effects of the combination were evaluated...
  47. ncbi request reprint Current management of metastatic gastrointestinal stromal tumor: a case report
    Suzanne George
    Dana Farber Cancer Institute, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Clin Adv Hematol Oncol 1:63-4; discussion 65. 2003
  48. ncbi request reprint Functional profiling of receptor tyrosine kinases and downstream signaling in human chondrosarcomas identifies pathways for rational targeted therapy
    Yi Xiang Zhang
    Ludwig Center at Dana Farber Harvard and Center for Sarcoma and Bone Oncology, Department of Medical Oncology, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 19:3796-807. 2013
    ..We sought to identify critical signaling pathways that contribute to their survival and proliferation, and which may provide potential targets for rational therapeutic interventions...
  49. pmc Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948)
    Chandrajit P Raut
    Department of Surgery, Brigham and Women s Hospital and Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 7:e26331. 2012
    ....
  50. ncbi request reprint Recombinant human erythropoietin in cancer-related anemia: an evidence-based review
    Jayesh Desai
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, Harvard Medical School, Shields Warren Building Room 530, 44 Binney Street, Boston, MA 02115, USA
    Best Pract Res Clin Haematol 18:389-406. 2005
    ....
  51. doi request reprint Major response to imatinib mesylate in KIT-mutated melanoma
    F Stephen Hodi
    The Melanoma Program, Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA, USA
    J Clin Oncol 26:2046-51. 2008
  52. ncbi request reprint A phase II study of troglitazone, an activator of the PPARgamma receptor, in patients with chemotherapy-resistant metastatic colorectal cancer
    Matthew H Kulke
    Department of Adult Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    Cancer J 8:395-9. 2002
    ..We therefore assessed the efficacy of troglitazone in the treatment of metastatic colon cancer in humans...
  53. ncbi request reprint Gastrointestinal stromal tumor: new nodule-within-a-mass pattern of recurrence after partial response to imatinib mesylate
    Sridhar Shankar
    Department of Radiology, Dana Farber Cancer Institute, Harvard Medical School, Boston, Mass, USA
    Radiology 235:892-8. 2005
    ..To investigate a new pattern of tumor recurrence observed at imaging in patients with metastatic gastrointestinal stromal tumor (GIST) after initial partial response to imatinib mesylate...
  54. ncbi request reprint Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity
    Thomas A Puchalski
    Dana Farber Partners Cancer Care, Harvard Medical School, Boston, Massachusetts, USA
    Cancer Chemother Pharmacol 50:309-19. 2002
    ....
  55. ncbi request reprint Familial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindred
    Frederick P Li
    Dana Farber Cancer Institute, 44 Binney St, Boston, MA 02115, USA
    J Clin Oncol 23:2735-43. 2005
    ..A tumor from the proband was analyzed to compare features with sporadic GISTs...
  56. ncbi request reprint Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor
    Sebastian Bauer
    Department of Pathology, Brigham and Women s Hospital, Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, and Ludwig Center at Dana Farber Harvard Cancer Center, Boston, Massachusetts 02115, USA
    Cancer Res 66:9153-61. 2006
    ..The dramatic inactivation of imatinib-resistant KIT oncoproteins suggests that HSP90 inhibition provides a therapeutic solution to the challenge of heterogeneous imatinib resistance mutations in GIST patients...
  57. ncbi request reprint Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study
    Harold J Burstein
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Breast Cancer Res Treat 79:391-7. 2003
    ..To evaluate the therapeutic effects of the peroxisome proliferator-activated receptor (PPAR) gamma activating ligand, troglitazone, in patients with refractory metastatic breast cancer...
  58. ncbi request reprint Liposarcoma subtypes: identification with computed tomography and ultrasound-guided percutaneous needle biopsy
    Paul Nikolaidis
    Department of Radiology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    Eur Radiol 15:383-9. 2005
    ..Although these data cannot be extrapolated to primary diagnosis of liposarcoma, they are important for screening and subtyping of possible recurrence...
  59. ncbi request reprint Mechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)
    Anette Duensing
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA
    Oncogene 23:3999-4006. 2004
    ....
  60. pmc Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification
    Katherine A Janeway
    Department of Pediatric Hematology Oncology, Dana Farber Cancer Institute and Children s Hospital, Boston, MA 02115, USA
    Int J Cancer 127:2718-22. 2010
    ..Despite the absence of apparent genomic activation mechanisms accounting for overexpression, clinical study of IGF1R-directed therapies in pediatric WT GIST is warranted...
  61. ncbi request reprint Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study
    R Garcia-Carbonero
    Dana Farber Cancer Institute, Harvard Medical School, 44 Binney St, Boston, Massachusetts 02115, USA
    J Clin Oncol 23:5484-92. 2005
    ..To evaluate the response rate, toxicity profile, and pharmacokinetics of ecteinascidin-743 (ET-743) as first-line therapy in patients with unresectable advanced soft tissue sarcoma (STS)...
  62. pmc Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor
    James E Butrynski
    Dana Farber Cancer Institute, Boston, MA 02115, USA
    N Engl J Med 363:1727-33. 2010
    ..Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.)...
  63. ncbi request reprint Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure
    S George
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    Eur J Cancer 45:1959-68. 2009
    ....
  64. pmc Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib
    Tammy F Chu
    Department of Cardiology, Children s Hospital Boston and Harvard Medical School, Boston, MA 02115, USA
    Lancet 370:2011-9. 2007
    ..We therefore assessed the cardiovascular risk associated with sunitinib in patients with metastatic gastrointestinal stromal tumours...
  65. ncbi request reprint KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway
    S Bauer
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02155, USA
    Oncogene 26:7560-8. 2007
    ..Targeting critical downstream signaling proteins, such as PI3-K, is a promising therapeutic strategy in imatinib-resistant GISTs...
  66. ncbi request reprint KIT oncoprotein interactions in gastrointestinal stromal tumors: therapeutic relevance
    M J Zhu
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Oncogene 26:6386-95. 2007
    ....
  67. ncbi request reprint High-throughput oncogene mutation profiling in human cancer
    Roman K Thomas
    Department of Medical Oncology, Dana Farber Cancer Institute, Harvard Medical School, 44 Binney Street, Boston, Massachusetts 02115, USA
    Nat Genet 39:347-51. 2007
    ..These results offer a new dimension in tumor genetics, where mutations involving multiple cancer genes may be interrogated simultaneously and in 'real time' to guide cancer classification and rational therapeutic intervention...
  68. pmc A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response
    Zhao Chen
    Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    Nature 483:613-7. 2012
    ....
  69. ncbi request reprint Aneurysmal bone cyst variant translocations upregulate USP6 transcription by promoter swapping with the ZNF9, COL1A1, TRAP150, and OMD genes
    Andre M Oliveira
    Department of Pathology, Brigham and Women s Hospital, Boston, MA 02115, USA
    Oncogene 24:3419-26. 2005
    ..In summary, these studies show that USP6 oncogenic activation results from heterogeneous genomic mechanisms involving USP6 transcriptional upregulation by juxtaposition with ectopic promoters...
  70. pmc Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations
    Katherine A Janeway
    Department of Pediatric Hematology Oncology, Dana Farber Cancer Institute and Children s Hospital, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 108:314-8. 2011
    ..Testing for germline mutations in SDH is recommended in patients with WT GIST. These findings highlight a potential central role of SDH dysregulation in WT GIST oncogenesis...
  71. ncbi request reprint Update on new diagnostic and therapeutic approaches for sarcomas
    Palma Dileo
    Dana Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Clin Adv Hematol Oncol 3:781-91. 2005
    ..The aim of this review is to provide a brief overview of the epidemiology, pathology, clinical presentation, and new approaches to the treatment of adult soft-tissue and bone sarcomas...
  72. pmc Aberrant AKT activation drives well-differentiated liposarcoma
    Alejandro Gutierrez
    Department of Pediatric Oncology, The Dana Farber Cancer Institute, MA 02215, USA
    Proc Natl Acad Sci U S A 108:16386-91. 2011
    ..Our findings are unique in providing an animal model to decipher the molecular pathogenesis of WDLPS, and implicate AKT as a previously unexplored therapeutic target in this chemoresistant sarcoma...
  73. doi request reprint Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial
    Andrew J Wagner
    Dana Farber Cancer Institute, Boston, Massachusetts, USA
    Cancer 118:5894-902. 2012
    ..This study assessed the activity of tivantinib (ARQ 197), a selective MET inhibitor, in patients with MiT-associated tumors...
  74. pmc Heterogeneity of kinase inhibitor resistance mechanisms in GIST
    B Liegl
    Department of Pathology, Brigham and Women s Hospital and Harvard Medical School, Boston, MA 02115, USA
    J Pathol 216:64-74. 2008
    ..Our observations underscore the heterogeneity of clinical TKI resistance, and highlight the therapeutic challenges involved in salvaging patients after clinical progression on TKI monotherapies...
  75. ncbi request reprint Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options
    G D Demetri
    Department of Adult Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02115, USA
    Semin Oncol 28:19-26. 2001
    ....
  76. pmc Therapeutic anti-EGFR antibody 806 generates responses in murine de novo EGFR mutant-dependent lung carcinomas
    Danan Li
    Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA
    J Clin Invest 117:346-52. 2007
    ..Taken together, these data support the hypothesis that mAb806 may lead to significant advancements in the treatment of the population of NSCLC patients with these 2 classes of EGFR mutations...
  77. ncbi request reprint Challenges in the development of platelet growth factors: low expectations for low counts
    Jennifer R Brown
    Department of Medical Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Curr Hematol Rep 1:110-8. 2002
    ....
  78. ncbi request reprint KIT activation is a ubiquitous feature of gastrointestinal stromal tumors
    B P Rubin
    Department of Pathology, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA
    Cancer Res 61:8118-21. 2001
    ..These studies underscore the role of KIT activation in GIST pathogenesis, and they suggest that activated KIT might represent a universal therapeutic target in GISTs...
  79. ncbi request reprint Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group
    G D Demetri
    Dana Farber Cancer Institute and Harvard Medical School, Boston, MA 02115, USA
    J Clin Oncol 16:3412-25. 1998
    ..To evaluate prospectively the effectiveness of epoetin alfa as an adjunct to chemotherapy in patients with cancer based on changes in quality-of-life parameters and hemoglobin levels, and to correlate these changes with antitumor response...
  80. pmc Anaemia and its functional consequences in cancer patients: current challenges in management and prospects for improving therapy
    G D Demetri
    Center for Sarcoma and Bone Oncology, Dana Farber Cancer Institute and Harvard Medical School, 44 Binney Street, Boston, MA 02115, USA
    Br J Cancer 84:31-7. 2001
    ..With this new option for therapy, further avenues of investigation should lead to renewed interest in the clinical benefits of optimal haemoglobin levels for patients with cancer...
  81. pmc Response to chemotherapy and predictors of survival in adult rhabdomyosarcoma
    N F Esnaola
    Division of Surgical Oncology, Department of Surgery, Radiation Oncology and Pathology, Brigham and Women's Hospital, Dana Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115, USA
    Ann Surg 234:215-23. 2001
    ..Future systemic therapies should be targeted to patients with localized/locoregional disease and partial responders to conventional chemotherapy...
  82. ncbi request reprint The biology of GM-CSF: regulation of production and interaction with its receptor
    J D Griffin
    Division of Tumor Immunology, Dana Farber Cancer Institute, Boston, Massachusetts 02115
    Int J Cell Cloning 8:35-44; discussion 44-5. 1990
    ..Signal transduction involves activation of a tyrosine kinase and possibly G protein-coupled stimulation of Na+/H+ exchange. The exact relationship of the two receptors needs further clarification...
  83. ncbi request reprint Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials
    John Glaspy
    University of California Los Angeles, Los Angeles, California, USA
    Oncologist 7:126-35. 2002
    ....
  84. ncbi request reprint Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer
    Francisco J Esteva
    University of Texas M D Anderson Cancer Center, and Baylor College of Medicine, Houston, Texas 77030, USA
    J Clin Oncol 21:999-1006. 2003
    ..However, it is an oral agent with minimal toxicity and a unique mechanism of action, which produced clinical benefit in approximately 20% of patients. Future efforts should define populations likely to benefit from this agent...
  85. ncbi request reprint GIST 1, chemotherapy 0, with a brand new hitter up next
    George D Demetri
    Cancer Invest 20:853-4. 2002
  86. ncbi request reprint Soft tissue sarcomas of adults: state of the translational science
    Ernest C Borden
    The Cleveland Clinic Foundation, Cleveland, Ohio, 44195, USA
    Clin Cancer Res 9:1941-56. 2003
    ..Finally, multicenter, coordinated trials, such as those that occurred with assessment of imatinib mesylate in metastatic gastrointestinal stromal tumors, will assure the most rapid reductions in morbidity and mortality...
  87. ncbi request reprint Safety and efficacy of the multidrug resistance inhibitor Incel (biricodar; VX-710) in combination with paclitaxel for advanced breast cancer refractory to paclitaxel
    Deborah Toppmeyer
    Cancer Institute of New Jersey, New Brunswick, New Jersey 08903, USA
    Clin Cancer Res 8:670-8. 2002
    ..This Phase II study evaluated the safety/tolerability, pharmacokinetics, and efficacy of VX-710 plus paclitaxel in women with locally advanced or metastatic breast cancer who were refractory to prior paclitaxel therapy...
  88. ncbi request reprint PDGFRA activating mutations in gastrointestinal stromal tumors
    Michael C Heinrich
    Department of Medicine, Department of Pathology, Oregon Health and Science University Cancer Institute and Portland VA Medical Center, Portland, OR 97201, USA
    Science 299:708-10. 2003
    ..Thus, KIT and PDGFRA mutations appear to be alternative and mutually exclusive oncogenic mechanisms in GISTs...
  89. ncbi request reprint Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy
    Jeffrey Crawford
    Duke Comprehensive Cancer Center, Duke University Medical Center, Durham, North Carolina, USA
    Cancer 95:888-95. 2002
    ..Relationships among hemoglobin, functional status, and patient reported QOL have not been well characterized...
  90. ncbi request reprint Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma
    Vivien H C Bramwell
    Department of Medical Oncology, London Regional Cancer Centre, 790 Commissioners Road, London, Ontario, Canada N6A 4L6
    Clin Cancer Res 8:383-93. 2002
    ..This Phase I/II study evaluated the safety/tolerability, pharmacokinetics, and efficacy of VX-710 plus doxorubicin in patients with inoperable, locally advanced or metastatic, anthracycline-resistant/refractory, soft tissue sarcoma...
  91. ncbi request reprint Nursing implications of imatinib as molecularly targeted therapy for gastrointestinal stromal tumors
    Jeanne M Griffin
    Clin J Oncol Nurs 9:161-9. 2005
    ..This article--based on published trials and clinical experience--summarizes the nursing implications, clinical efficacy, and safety of imatinib as an effective and rationally targeted treatment for GIST...
  92. ncbi request reprint NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)--update of the NCCN clinical practice guidelines
    George D Demetri
    J Natl Compr Canc Netw 5:S1-29; quiz S30. 2007
    ....
  93. ncbi request reprint Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor)
    Michael C Heinrich
    Oregon Health and Science University Cancer Institute and Portland VA Medical Center, Portland, OR, USA
    J Clin Oncol 24:1195-203. 2006
    ..To determine the clinical efficacy of imatinib in patients with advanced aggressive fibromatosis (AF) and to identify the molecular basis of response/nonresponse to this agent...
  94. ncbi request reprint CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor
    Clay H Holdsworth
    Massachusetts College of Pharmacy and Health Sciences, 4 Brook Rd, Unit 11, Salem, NH 03079, USA
    AJR Am J Roentgenol 189:W324-30. 2007
    ....
  95. ncbi request reprint Cancer- and treatment-related anemia
    George M Rodgers
    J Natl Compr Canc Netw 3:772-89. 2005
  96. ncbi request reprint Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study
    Federica Grosso
    Cancer Medicine Department, Adult Sarcoma Medical Treatment Unit, IRCCS Foundation National Cancer Institute, Milan, Italy
    Lancet Oncol 8:595-602. 2007
    ....
  97. doi request reprint Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT
    Charles D Blanke
    Oregon Health and Science University Cancer Center and Portland Veterans Affairs Hospital, Portland, OR, USA
    J Clin Oncol 26:620-5. 2008
    ..We conducted a long-term analysis of patients treated on the trial, including patients followed during an extension phase, to evaluate survival, patterns of failure, and potential prognostic factors, including tumor mutational status...
  98. doi request reprint Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033
    Charles D Blanke
    Oregon Health and Science University Cancer Institute, 3181 SW Sam Jackson Park Rd, L 586, Portland, OR 97239, USA
    J Clin Oncol 26:626-32. 2008
    ....
  99. doi request reprint A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib
    Tejas V Patel
    J Natl Cancer Inst 100:282-4. 2008
  100. doi request reprint Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases
    Michael C Heinrich
    Department of Hematology and Medical Oncology, Oregon Health and Science University Cancer Institute and Portland VA Medical Center, Portland, Oregon 97239 3098, USA
    Clin Cancer Res 14:2717-25. 2008
    ..To evaluate the activity of imatinib in treating advanced, life-threatening malignancies expressing one or more imatinib-sensitive tyrosine kinases...
  101. ncbi request reprint Phase II study of ecteinascidin 743 in heavily pretreated patients with recurrent osteosarcoma
    Caroline Laverdiere
    Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    Cancer 98:832-40. 2003
    ..Recurrent osteosarcoma is a drug-resistant disease with a dismal prognosis. The objective of this Phase II study was to evaluate the activity of ecteinascidin 743 (ET-743) as a salvage therapy in these patients...